GlassScriptPhysician profile
Christopher Lee Vendryes
NPI 1457663924
$6,693.36
in general payments reported to CMS, 2019-2025
34 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $913 · 2021: $1,548 · 2022: $1,050 · 2023: $788 · 2024: $413 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,463.02 | 2019-2025 | Ams 700, Rezum Generator, Lithovue |
| Janssen Biotech, INC. | $533.75 | 2019-2024 | Erleada |
| Endo Pharmaceuticals INC. | $396.57 | 2019-2022 | |
| Procept Biorobotics Corporation | $352.41 | 2023-2025 | Aquabeam Robotic System |
| Coloplast Corp | $291.49 | 2019-2023 | Speedicath |
| Astellas Pharma US INC | $266.99 | 2020-2023 | Myrbetriq, Veozah |
| Abbvie INC. | $153.04 | 2020-2024 | Lupron Depot |
| Bayer Healthcare Pharmaceuticals INC. | $142.36 | 2021-2023 | |
| Pfizer INC. | $113.15 | 2019-2025 | |
| Endo USA, INC. | $96.24 | 2024-2025 | Xiaflex |
| Laborie Medical Technologies Corp. | $82.06 | 2023-2025 | Endosheath Technology, Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $80.38 | 2021-2022 | |
| Tolmar, INC. | $80.02 | 2024-2025 | Eligard, Jatenzo |
| Verity Pharmaceuticals INC. | $77.56 | 2022-2025 | Tlando |
| Convatec INC. | $59.11 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.05 | 2021-2023 | Lynparza |
| Antares Pharma, INC. | $48.36 | 2025 | Xyosted |
| Tolmar Pharmaceuticals, INC. | $46.16 | 2022 | |
| Immunitybio, INC. | $40.26 | 2025 | |
| Myriad Genetic Laboratories, INC. | $36.78 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $33.44 | 2022-2024 | Bard Urinary Drainage Bag |
| Alnylam Pharmaceuticals INC. | $26.59 | 2023 | Givlaari |
| Acerus Pharmaceuticals Corporation | $26.56 | 2022 | |
| Spinal Simplicity, LLC | $22.78 | 2023 | Ha Minuteman G3-R |
| Teleflex LLC | $21.89 | 2024 | Urolift |
| Medtronic, INC. | $20.56 | 2025 | Altaviva |
| Curonix LLC | $20.55 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ardelyx, INC. | $18.75 | 2023 | Ibsrela |
| Axonics, INC. | $17.99 | 2022 | |
| Ambu INC. | $17.73 | 2021 | |
| Olympus America INC. | $17.35 | 2025 | Itind System |
| Philips North America LLC | $16.24 | 2025 | Oncology Solution |
| Angiodynamics, INC. | $12.77 | 2022 | |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vendryes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.